Sex differences in aging, life span and spontaneous tumorigenesis in 129/Sv mice neonatally exposed to metformin http://www.tandfonline.com/doi/pdf/10.4161/15384101.2014.973308

Cell Cycle

Volumn 14, Issue 1, 2015, Pages 46-55

  Anisimov, Vladimir ^a   Popovich, Irina G ^a   Zabezhinski, Mark A ^a   Egormin, Peter A ^a   Yurova, Maria N ^a   Semenchenko, Anna V ^a   Tyndyk, Margarita L ^a   Panchenko, Andrey V ^a   Trashkov, Alexandr P ^a,b   Vasiliev, Andrey G ^a,b   Khaitsev, Nikolai V ^a,b  

^a N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^b SAINT PETERSBURG STATE PEDIATRIC MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Biomarkers of aging; Carcinogenesis; Gender; Life extension; Metformin; Mice; Neonatal

Indexed keywords

CHOLESTEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; GROWTH HORMONE; HEMOGLOBIN; INSULIN; METFORMIN; NITROGEN OXIDE; SOMATOMEDIN; SUPEROXIDE; THYROXINE; VASCULOTROPIN; ANTIDIABETIC AGENT; SOMATOMEDIN C; TARGET OF RAPAMYCIN KINASE;

AGE; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; FLUID INTAKE; FOOD INTAKE; LIFE EXTENSION; LIFESPAN; MALE; METABOLIC PARAMETERS; MOUSE; NEWBORN CARE; NONHUMAN; PERINATAL DRUG EXPOSURE; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SURVIVAL TIME; SURVIVOR; WEIGHT REDUCTION; 129 MOUSE; ANIMAL; BODY TEMPERATURE; BODY WEIGHT; CELL TRANSFORMATION; DRUG EFFECTS; ESTRUS CYCLE; LONGEVITY; METABOLISM; NEWBORN; PREGNANCY; PROPORTIONAL HAZARDS MODEL;

MUS; RODENTIA;

AGING; ANIMALS; ANIMALS, NEWBORN; BODY TEMPERATURE; BODY WEIGHT; CELL TRANSFORMATION, NEOPLASTIC; ESTROUS CYCLE; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN-LIKE GROWTH FACTOR I; LONGEVITY; MALE; METFORMIN; MICE; MICE, 129 STRAIN; PREGNANCY; PROPORTIONAL HAZARDS MODELS; SEX FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84921884953     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/15384101.2014.973308     Document Type: Article

References (54)

1. Bartke A, Chandrashekar V, Dominici F, TurynD, Kinney B, Steger R, Kopchick JJ. Insulin-like growth factor 1 (IGF- 1) and aging: controverses and new insights. Biogerontology 2003; 4:1-8; PMID:12652183; http://dx.doi.org/10.1023/A:1022448532248
2. Anisimov VN, Bartke A. The key role of growth hormone-insulin-IGF-1 signaling in aging and cancer. Crit Rev Oncol Hematol 2013; 87:201-23; PMID:23434537; http://dx.doi.org/10.1016/j.critrevonc.2013.01.005
3. Yaun R, Tsaih SW, Petkova SB, Marin de Evsikova C, Xing S, Marion MA, Bogue MA, Mills KD, Peters LL, Bult CJ, et al. Aging in inbred stains of mice: study design and interim report of median lifespans and circulating IGF1 levels. Aging Cell 2009; 8:277-87; PMID:19627267; http://dx.doi.org/10.1111/j.1474-9726.2009.00478.x
4. Williams G. Pleiotropy, natural selection, and evolution of senescence. Evolution 1957; 11:398-411; http://dx.doi.org/10.2307/2406060
5. Levin BE. Metabolic imprinting: critical impact of the perinatal environment on the regulation of energy homeostasis. Philos Trans R Soc London B Biol Ser 2006; 361:1107-21; http://dx.doi.org/10.1098/rstb.2006.1851
6. Nugent BM, Tobet SA, Lara HE, Lucion AB, Wilson ME, Rexabarren SE, Paredes AH. Hormonal programming across the life span. Horm Metab Res 2012; 44:577-86; PMID:22700441; http://dx.doi.org/10.1055/s-0032-1312593
7. Vickers MH. Early life nutrition, epigenetics and programming of late life disease. Nutrients 2014; 6.16502178; http://dx.doi.org/10.3390/nu6062165
8. Barker DJ. The fetal and infant origin of adult disease. BMJ 1990; 3901:1111; http://dx.doi.org/10.1136/bmj.301.6761.1111
9. Hadley EC, Dutta C, Finkelstein J, Harris TB, Lane MA, Roth GS, Sherman SS, Starke-Reed PE. Human implications of caloric restriction's effect on laboratory animals: an overview of opportunities for research. J Gerontol Ser A 2001; 56A (Special issue I):5-6; http://dx.doi.org/10.1093/gerona/56.suppl-1.5
10. Ingram DK, Zhu M, Mamczarz J, Zou S, Lane MA, Roth GS, deCabo R. Calorie restriction mimetics: an emerging research field. Aging Cell 2006; 5:97-108; PMID:16626389; http://dx.doi.org/10.1111/j.1474-9726.2006.00202.x
11. Mattson MP, Duan W, Lee J, Guo Z, Roth GS, Ingram DK, Lane MA. Progress in the development of caloric restriction mimetic dietary supplements. J Anti-Aging Med 2001; 4:225-32; http://dx.doi.org/10.1089/109454501753249993
12. Spindler SR. Caloric restriction: from soup to nuts. Ageing Res Rev 2010; 9:324-53; PMID:19853062; http://dx.doi.org/10.1016/j.arr.2009.10.003
13. Dilman VM. Development, Aging and Disease. A New Rationale for an Intervention. Chur: Harwood Academic Publishers 1994.
14. Dilman VM, Anisimov VN. Effect of treatment with phenformin, dyphenylhydantoin or L-DOPA on life span and tumor incidence in C3HSn mice. Gerontology 1980; 26:241-5; PMID:7390164; http://dx.doi.org/10.1159/000212423
15. Anisimov VN. Carcinogenesis and Aging. Vol. 2. Boca Raton: CRC Press, 1987.
16. Anisimov VN, Semenchenko AV, Yashin AI. Insulin and longevity: antidiabetic biguanides as geroprotectors. Biogerontology 2003; 4:297-307; PMID: 14618027; http://dx.doi.org/10.1023/A:1026299318315
17. Blagosklonny MV. An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today 2007; 12:218-24; PMID:17331886; http://dx.doi.org/10.1016/j.drudis.2007.01.004
18. Blagosklonny MV. Prevention of cancer by inhibiting aging. Cancer Biol Ther 2008; 7:1520-4; PMID: 18769112; http://dx.doi.org/10.4161/cbt.7.10.6663
19. Berstein LM. Biguanides: An Expansion to Practical Oncology (past and present). St.Petersburg: Aesculap, 2010.
20. Kruse JA. Review: metformin does not increase risk for lactic acidosis or increase lactate levels in type 2 diabetes. ACP J Club 2004; 141:7; PMID:15230555
21. Nisbet JC, Strurtevant JM, Prins JB. Metformin and serious adverse effects. Med J Aust 2004; 180:53-4; PMID:14723582
22. Vidal-Alaball J, Butler CC. Reduced serum vitamin B-12 in patients taking metformin. BMJ 2010; 340: c2198; PMID:20488912; http://dx.doi.org/10.1136/bmj.c2198
23. Krentz AJ, Ferner RE, Balley CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Safety 1994; 11:223-41; PMID:7848543; http://dx.doi.org/10.2165/00002018-199411040-00002
24. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Kovalenko IG, Poroshina TE, Semenchenko AV, Provinciali M, et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2neu transgenic mice. Exp Gerontol 2005; 40:685-93; PMID:16125352; http://dx.doi.org/10.1016/j.exger.2005.07.007
25. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MV, Zabezhinski MA, Anikin IV, Karkach AS, Romanyukha AA. Metformin extends life span of HER-2neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 2010; 9:188-97; PMID:20016287; http://dx.doi.org/10.4161/cc.9.1.10407
26. Anisimov VN, Berstein LM, Egormin PA, Piskunova TS, Popovich IG, Zabezhinski MA, Tyndyk ML, Yurova MN, Kovalenko IG, Poroshina TE, et al. Metformin slows down aging and extends life span of female SHR mice. Cell Cycle 2008; 7:2769-73; PMID:18728386; http://dx.doi.org/10.4161/cc.7.17.6625
27. Smith DL, Elam CF, Mattison JA, Lane MA, Roth GS, Ingram DK, Allison DB. Metformin supplementation and life span in Fischer-344 rats. J Gerontol Biol Sci 2010; 65A:468-74; http://dx.doi.org/10.1093/gerona/glq033
28. Anisimov VN, Piskunova TS, Popovich IG Zabezhinski MA, Tyndyk ML, Egormin PA, Yurova MV, Rosenfeld SV, Semenchenko AV, Kovalenko IG, et al. Gender differences in metformin effects on aging, life span and spontaneous tumorigenesis in 129Sv mice. Aging (Albany, NY) 2010; 2:945-57; PMID:21164223
29. Cox DR, Oakes D. Analysis of Survival Data. London: Chapman & Hall, 1996.
30. Piskunova TS, Yurova MN, Ovsjannikov AI, Semenchenko AV, Zabezhinski MA, Popovich IG, Wang ZQ, Anisimov VN. Deficiency in poly(ADP-ribose) polymerase-1 (PARP-1) accelerates aging and spontaneous carcinogenesis in mice. Current Gerontol Geriatr Res 2008; 754190:11; http://dx.doi.org/10.1155/2008/754190; PMID:19415146
31. Quin BJ, Dallos M, Kitagawa H, Kunnumakkara AB, Memmott RM, Hollander MC, Gills JJ, Dennis PA. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling. Cancer Prev Res (Phila) 2013; 6:801-10; PMID:23771523; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0058-T
32. Salomaki H, Vahatal LH, Laurila K, Jappinen NT, Penmttinen A-M, Ailanen L, Ilyazadeh J, Pesonen U, Koulu M. Prenatal metformin exposure in mice programs the metabolic phenotype of the offspring during a high fat diet at adulthood. PLoS One 8(2):e56594; PMID:23457588; http://dx.doi.org/10.1371/journal.pone.0056594
33. Panici JA, Harper JM, Miller RA, Bartke A, Spong A, Masternak MM. Early life growth hormone treatment shortens longevity and decreases cellular stress resistance in long-lived mutant mice.FASEB J 2010; 24:5073-9; http://dx.doi.org/10.1096/fj.10-163253
34. Anisimov VN. Metformin for aging and cancer prevention. Aging (Albany NY) 2010; 2:760-74; PMID:21084729
35. Anisimov VN. Metformin: do we finally have an antiaging drug? Cell Cycle 2013; 12:3483-9; PMID:24189526; http://dx.doi.org/10.4161/cc.26928
36. Anisimov VN. Do metformin a real anticarcinogen? A critical reappraisal of experimental data. Ann Transl Med 2014; 2(6); http://dx.doi.org/10.3978/j.issn.2305-5839.2014.06.02
37. Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Metformin and cancer. Doses, mechanisms and the dandelion and hermetic phenomena. Cell Cycle 2010; 9:1057-64; PMID:20305377; http://dx.doi.org/10.4161/cc.9.6.10994
38. Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, Minor RK, Blouin MJ, et al. Metformin improves healthspan and lifespan in mice. Nat Commun 2013; 4:2192; PMID:23900241; http://dx.doi.org/10.1038/ncomms3192
39. Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, Nadon NL, Wilkinson JE, Frenkel K, Carter CS, et al. Rapamycin fed late in life extends lifespan in genetically heterogenous mice. Nature 2009; 460:392-6; PMID:19587680
40. Selman C, Tullet JMA, Wieser D, Irvine E, Lingard SJ, Cloudhury AI, Claret M, Al-Quassab H, Carmignac D, Ramadani F, et al. Ribosomal protein S6 kinase 1 signaling regulates mammalian life span. Science 2009; 326:140-4; PMID:19797661; http://dx.doi.org/10.1126/science.1177221
41. Awartani, KA, Cheung AP. Metformin and polycystic ovary syndrome: a literature review. J Obstet Gynecol Can 2002; 24:393-401.
42. Orecchioni S, Reggiani F, Talarico G, Mancuso P, Calleri A, Gregato G, Labanca V, Noonan DM, Dallaglio K, Albini A, et al. The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. Int J Cancer 2014; Sep 6. PMID:25196138; http://dx.doi.org/10.1002/ijc.29193
43. Parkhitko AA, Favorova OO, Khabibullin DI, Anisimov VN, Henske EP. Kinase mTOR: regulation and role in maintenance of cellular homeostasis, tumor development, and aging. Biochemistry (Moscow) 2014; 79(2):88-101; http://dx.doi.org/10.1134/S0006297914020023
44. Menendez JA, Joven J. Energy metabolism and metabolic sensors in stem cells: the metabolistem crossroads of aging and cancer. Adv Exp Med Biol 2014; 824:117-39; PMID:25038997; http://dx.doi.org/10.1007/978-3-319-07320-0-10
45. Andrzejewski S, Gravel S-P, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab 2014; 2:12; PMID:25184038; http://dx.doi.org/10.1186/2049-3002-2-12
46. Leontieva OV, Paszkiewicz GM, Blagosklonny MV. Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging. Aging (Albany NY).2012; 4(12):899-916; PMID:23443503
47. Blagosklonny MV. Big mice die young but large animals live longer. Aging (Albany NY) 2013; 5(4):227-33; PMID:23603822
48. Blagosklonny MV. M(o)TOR of aging: MTOR as a universal molecular hypothalamus. Aging (Albany NY) 2013; 5(7):490-4; PMID:23872658
49. Anisimov VN, Popovich IG, Zabezhinski MA. Methods of evaluating the effect of of pharmacological drugs on aging and life span in mice. Methods Mol Biol 2007; 371:227-36; PMID:17634585; http://dx.doi.org/10.1007/978-1-59745-361-5-17
50. Turusov VS, Mohr U (Eds) Pathology of Tumours in Laboratory Animals. Volume 2. Tumours of the Mouse (2nd ed). IARC Sci Publ 111, Lyon: IARC 1994.
51. Goubler EV. Computing Methods of Pathology Analysis and Recognition. Leningrad: Meditsina, 1978.
52. Fletcher R. Practical Methods of Optimization (2nd ed.). New York: Wiley 1987.
53. Davison AC, Hinkley DV. Bootstrap Methods and Their Application, Cambridge: Cambridge University Press, 1997.
54. Cox D. Regression models and life-tables (with discussion). J Royal Stat Soc Series B (Methodological) 1972; 34:187-220.